Welcome to our dedicated page for Glucotrack news (Ticker: GCTK), a resource for investors and traders seeking the latest updates and insights on Glucotrack stock.
Glucotrack (GCTK) delivers innovative diabetes management solutions through non-invasive and implantable glucose monitoring technologies. This dedicated news hub provides investors and healthcare professionals with essential updates on the company's clinical advancements and market developments.
Access real-time information about regulatory milestones, product certifications, and strategic partnerships. Our curated feed includes earnings reports, clinical trial outcomes, and technology updates directly impacting GCTK's position in the medical device sector.
Key coverage areas include FDA/EU regulatory progress, implantable CBGM system trials, and commercial expansion initiatives. Bookmark this page for streamlined tracking of Glucotrack's progress in revolutionizing blood glucose measurement through cutting-edge ultrasound and electromagnetic technologies.
GlucoTrack, Inc. (NASDAQ:GCTK) announced a $10 million underwritten public offering led by Aegis Capital Corp. as the sole bookrunner on April 17, 2023. The funds are intended to support the company's mission of developing non-invasive glucose monitoring devices for diabetes patients. Founded in 2001 and based in Or Yehuda, Israel, GlucoTrack is focused on providing an alternative to traditional glucose measurement methods, thereby improving the quality of life for diabetics and pre-diabetics. The company aims to enhance its product offerings and expand its market reach with the new capital raised from this offering.
GlucoTrack, Inc. (GCTK) announced the completion of a public offering that raised approximately $10.0 million. This offering included 7,352,942 shares of common stock priced at $1.36 per share, along with pre-funded warrants. The funds will primarily be utilized for working capital and general corporate purposes, potentially covering acquisitions, marketing efforts, and operational costs. The transaction was managed by Aegis Capital Corp. and conducted under an existing shelf registration statement. This development underscores GlucoTrack's commitment to expanding its operations in the diabetes management sector and enhancing its non-invasive glucose monitoring technology.
GlucoTrack, Inc. (NASDAQ: GCTK) announced a firm commitment underwritten public offering of 7,352,942 shares of common stock priced at $1.36 per share, aiming to raise approximately $10 million in gross proceeds. The offering is set to close on April 17, 2023, subject to customary conditions. Proceeds will be allocated for working capital and general corporate purposes, including potential acquisitions, sales and marketing, and capital expenditures. Aegis Capital Corp. is the sole book-running manager for this offering, conducted under an effective shelf registration statement.
GlucoTrack specializes in the design and development of non-invasive glucose monitoring devices aimed at easing diabetes management.
GlucoTrack, Inc. (Nasdaq: GCTK) announced a firm commitment underwritten public offering of common stock on April 12, 2023. The funds raised will primarily support working capital and general corporate purposes, including potential acquisitions and sales and marketing efforts. The offering is contingent on market conditions, and specific details regarding size and terms will be disclosed later. Aegis Capital Corp. is the sole book-running manager of this offering, which is executed under an effective shelf registration statement previously filed with the SEC. Investors are advised to review the upcoming prospectus supplement for detailed information.
GlucoTrack, Inc. (Nasdaq: GCTK) provided an update from CEO Paul V. Goode, detailing progress in its business strategy focused on diabetes solutions. The company is developing an innovative non-invasive glucose monitoring device and has acquired technology for an implantable continuous glucose monitor for Type 1 diabetes. GlucoTrack's Gen 2 device aims to miniaturize technology, improving user experience with a measurement time reduction from 60 seconds to 2 seconds. Clinical prototypes are in development, with first-in-human studies expected in Q2 2023, targeting FDA submission for a commercial device by late Q3 2023.
On October 27, 2022, The Power Play by The Market Herald featured interviews with several companies, including GlucoTrack (GCTK). GlucoTrack announced the hiring of Mark Tapsak, Ph.D., as Vice President of Sensor Technology, bringing over 25 years of experience in the diabetes industry. The news emphasizes the company's commitment to enhancing its product technology through experienced personnel. Other highlighted companies include NextSource, good natured Products, SoLVBL, and Geologica, who also shared significant updates regarding their operations and financial performance.
GlucoTrack (Nasdaq: GCTK) appointed Mark Tapsak, PhD, as Vice President of Sensor Technology, effective October 14, 2022. Tapsak brings over 25 years of experience in diabetes management and will lead the R&D for a new implantable continuous glucose monitoring system aimed at Type 1 diabetes. He has held senior roles at notable companies including Dexcom and Medtronic. CEO Paul Goode expressed excitement about Tapsak's expertise, aiming to develop innovative products that enhance patient comfort and health management.
